These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10912577)

  • 1. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
    Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
    Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
    Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
    J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
    Saltz LB; Spriggs D; Schaaf LJ; Schwartz GK; Ilson D; Kemeny N; Kanowitz J; Steger C; Eng M; Albanese P; Semple D; Hanover CK; Elfring GL; Miller LL; Kelsen D
    J Clin Oncol; 1998 Dec; 16(12):3858-65. PubMed ID: 9850031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
    J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
    Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
    Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
    J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
    Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR
    Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
    Murren JR; Anderson S; Fedele J; Pizzorno G; Belliveau D; Zelterman D; Burtness BA; Tocino I; Flynn SD; Beidler D; Cheng YC
    J Clin Oncol; 1997 Jan; 15(1):148-57. PubMed ID: 8996136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
    de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
    J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
    Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
    J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
    Tew WP; Radovich D; O'Reilly E; Schwartz G; Schrag D; Saltz LB; Kelsen DP; Kepler S; Ilson DH
    Invest New Drugs; 2009 Aug; 27(4):366-73. PubMed ID: 18956138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
    Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
    Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
    de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
    J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.